NCT04587128View on ClinicalTrials.gov

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

PHASE2RecruitingINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

October 19, 2020

Primary Completion Date

October 31, 2033

Study Completion Date

October 31, 2033

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Panitumumab

Epidermal growth factor receptor inhibitor, anti-neoplastic

DRUG

Cetuximab

Epidermal growth factor receptor inhibitor, anti-neoplastic

DRUG

Irinotecan

anti-neoplastic, chemotherapy drug

DRUG

FOLFIRI Protocol

folinic acid (also called leucovorin, calcium folinate or FA) fluorouracil (also called 5FU) irinotecan given per institutional standard (intravenously day 1 and day 15 of 28 day cycle) alternating and not concomitant with panitumumab or cetuximab

DRUG

Bevacizumab

Bevacizumab (or biosimilar) may be administered with FOLFIRI per treating MD discretion and will be given per institutional standard (5 mg/kg intravenously day 1 and day 15 of 28 day cycle)

Trial Locations (1)

53792

RECRUITING

University of Wisconsin Carbone Cancer Center, Madison

All Listed Sponsors
collaborator

Doris Duke Charitable Foundation

OTHER

lead

University of Wisconsin, Madison

OTHER